NZ586025A - Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate - Google Patents

Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate

Info

Publication number
NZ586025A
NZ586025A NZ586025A NZ58602509A NZ586025A NZ 586025 A NZ586025 A NZ 586025A NZ 586025 A NZ586025 A NZ 586025A NZ 58602509 A NZ58602509 A NZ 58602509A NZ 586025 A NZ586025 A NZ 586025A
Authority
NZ
New Zealand
Prior art keywords
ethyl acrylate
acrylate copolymer
methacrylic acid
tablet
rasagiline mesylate
Prior art date
Application number
NZ586025A
Other languages
English (en)
Inventor
Muhammad Safadi
Dannit Licht
Rachel Cohen
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ586025A publication Critical patent/NZ586025A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ586025A 2008-01-11 2009-01-09 Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate NZ586025A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1086008P 2008-01-11 2008-01-11
PCT/US2009/000134 WO2009089049A1 (en) 2008-01-11 2009-01-09 Rasagiline formulations, their preparation and use

Publications (1)

Publication Number Publication Date
NZ586025A true NZ586025A (en) 2012-08-31

Family

ID=40850833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586025A NZ586025A (en) 2008-01-11 2009-01-09 Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate

Country Status (15)

Country Link
US (1) US20090181086A1 (enExample)
EP (1) EP2234478A4 (enExample)
JP (2) JP5583597B2 (enExample)
KR (1) KR20100107028A (enExample)
CN (1) CN101909438A (enExample)
AU (1) AU2009204454B2 (enExample)
BR (1) BRPI0905680A2 (enExample)
CA (1) CA2711817A1 (enExample)
EA (1) EA201070842A1 (enExample)
IL (1) IL206136A0 (enExample)
MX (1) MX2010007601A (enExample)
NZ (1) NZ586025A (enExample)
SG (1) SG187455A1 (enExample)
WO (1) WO2009089049A1 (enExample)
ZA (1) ZA201004086B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
AU2010341499A1 (en) 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
WO2013055687A2 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
WO2024098098A1 (en) * 2022-11-07 2024-05-16 Natural MedTech Pty Ltd Tryptamine formulations and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
FI955979L (fi) * 1993-06-14 1995-12-13 Janssen Pharmaceutica Nv Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP0966435B1 (en) * 1996-12-18 2005-04-06 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20050220864A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
EP1663167A1 (en) * 2004-07-26 2006-06-07 Teva Pharmaceutical Industries Ltd Dosage forms with an enterically coated core tablet
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
CA2600011C (en) * 2005-02-23 2015-11-10 Teva Pharmaceutical Industries Ltd. Rasagiline formulations of improved content uniformity
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
JP5701485B2 (ja) * 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
MX2010013766A (es) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
MX2010013875A (es) * 2008-06-19 2011-01-20 Teva Pharma Proceso para preparar y secar base de rasagilina solida.
EP2328861A2 (en) * 2008-07-11 2011-06-08 Synthon BV Polymorphs of rasagiline hydrochloride
US20100029987A1 (en) * 2008-07-29 2010-02-04 Dipharma Francis S.R.I. Crystalline Form of Rasagiline and Process for the Preparation Thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
AU2010341499A1 (en) * 2009-12-22 2012-08-09 Teva Pharmaceutical Industries Ltd. 3-keto-N-propargyl-1-aminoindan
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
CN103188933A (zh) * 2010-10-26 2013-07-03 泰华制药工业有限公司 富集氘的雷沙吉兰
JP2014534195A (ja) * 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトルアミド
EP2766004A4 (en) * 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
WO2013055687A2 (en) * 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-formyl-propargyl-aminoindan

Also Published As

Publication number Publication date
AU2009204454B2 (en) 2015-02-05
JP2011509295A (ja) 2011-03-24
EP2234478A1 (en) 2010-10-06
AU2009204454A1 (en) 2009-07-16
MX2010007601A (es) 2010-08-03
US20090181086A1 (en) 2009-07-16
BRPI0905680A2 (pt) 2015-07-07
SG187455A1 (en) 2013-02-28
WO2009089049A1 (en) 2009-07-16
EP2234478A4 (en) 2013-01-23
EA201070842A1 (ru) 2011-04-29
IL206136A0 (en) 2010-11-30
CN101909438A (zh) 2010-12-08
KR20100107028A (ko) 2010-10-04
ZA201004086B (en) 2011-08-31
JP5583597B2 (ja) 2014-09-03
JP2014237668A (ja) 2014-12-18
CA2711817A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
NZ586025A (en) Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
JP2011509295A5 (enExample)
JP2017128614A5 (enExample)
JP2020023518A5 (enExample)
JP2014506321A5 (enExample)
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ620879A (en) A novel formulation of indomethacin
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ620887A (en) A novel formulation of diclofenac
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
JP2009280621A5 (enExample)
CA2393437A1 (en) Exo-s-mecamylamine formulation and use in treatment
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
NZ606825A (en) Methods and compositions for treating complement-associated disorders
NZ598534A (en) Dosage regimen of an s1p receptor modulator
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2013507352A5 (enExample)
JP2011225596A5 (enExample)
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2013502446A5 (enExample)
JP2014534197A5 (enExample)
RU2015140572A (ru) Способы лечения колоректального рака
JP2012502103A5 (enExample)

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2016 BY DENNEMEYER SA

Effective date: 20130308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2019 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 09 JAN 2029 BY DENNEMEYER + CO

Effective date: 20140828

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2022 BY DENNEMYER + CO

Effective date: 20140828